Abivax to host KOL Investor Event to review phase 2b clinical data and phase 3 trial design for obefazimod in patients with moderately to severely active ulcerative colitis on February 6, 2024 PARIS, France, January 24, 2024, 8:30 a.m. CET – Abivax SA ((Euronext Paris &amp, NASDAQ:ABVX) ("Abivax" or the "Company"), a clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to modulate the immune response in patients with chronic inflammato ...

Abivax provides 2024 strategic outlook and lays out key milestones over next 12 months Induction data read-out expected Q1 2025 from the pivotal Phase 3 ABTECT program evaluating obefazimod in moderately to severely active ulcerative colitis (UC) Formal process evaluating oral and injectable combination therapy candidates with obefazimod in UC has commenced; preclinical data to support decision-making on combination agent expected in 2H 2024Top-line data from long-term extension trial with 25mg obefazimod o ...

Abivax 2024 Financial Communication Calendar PARIS, France, January 4, 2024, 8:30 a.m. CET – Abivax SA ((Euronext Paris &amp, NASDAQ:ABVX) ("Abivax" or the "Company"), a clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases, today publishes its 2024 financial communication calendar. Tuesday, April 2, 20242023 Annual Business and Financial Report (as of Decemb ...